Abstract
Currently, many novel therapies are available for physicians treating cancer; some of them are associated with adverse cardiac events. One of the most worrisome cardiac event is QT prolongation, which is a risk factor for developing the potentially fatal torsade de pointe. Many classes of drugs, both anticancer and concomitant agents, are involved in this issue. We report a review of old and new commonly used agents with torsadogenic potential.
Keywords: Adverse cardiac events, cancer, QT prolongation, through QT study, torsade de point.
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
Article Metrics
31
2